Obesity is widely known for increasing the risk of diabetes and cardiovascular disease, but its damaging effects on the skeleton are often overlooked. Excess body fat can disrupt bone metabolism, weaken bone quality, and impair fracture repair. In individuals with metabolic disorders, bone marrow can accumulate fat cells that interfere with the activity of bone-forming cells and damage the vascular networks that support skeletal tissue. These changes increase fracture risk and reduce the body's ability to regenerate bone after injury. Despite these clinical challenges, the biological mechanisms connecting metabolic disease and bone health have remained poorly understood.
To explore this connection, a team of researchers led by Professor Christa Maes from the Laboratory of Skeletal Cell Biology and Physiology, KU Leuven, Belgium, investigated the role of hypoxia-inducible factor (HIF) signaling, a molecular pathway that enables cells to adapt to low-oxygen environments while regulating metabolism, blood vessel formation, and tissue repair. Using a mouse model of high-fat diet (HFD)-induced obesity, the team administered the HIF-prolyl-hydroxylase-domain enzyme (PHD) inhibitor FG-4592 (Roxadustat), a drug already approved for treating certain forms of anemia. Mice were fed HFD to mimic metabolic stress, allowing the researchers to examine whether activating hypoxia signaling could improve both metabolic health and skeletal integrity under obesogenic conditions. Their findings were published in Volume 14 of the journal Bone Research on February 11, 2026.
"We hypothesize that activation of the HIF pathway might be an effective therapeutic strategy to enhance both metabolism and skeletal integrity during metabolic stress," says Prof. Maes.
The experiments revealed striking metabolic benefits in the treated animals. Activation of the hypoxia signaling pathway significantly reduced body-weight gain and limited the accumulation of peripheral fat despite continued exposure to HFD. The treated mice also showed improved glucose tolerance, indicating better control of blood sugar levels. Researchers found that these metabolic improvements were associated with increased energy expenditure, suggesting that the intervention helped the body burn more energy rather than storing it as fat.
Equally important were the protective effects on bone tissue. Obesity often leads to excessive accumulation of adipocytes in bone marrow, which disrupts the balance between bone formation and fat storage. In the treated mice, activation of HIF signaling prevented this abnormal buildup of marrow fat while preserving the vascular network within bone. Maintaining this blood vessel system is essential because it supplies oxygen, nutrients, and molecular signals that support bone maintenance and regeneration.
The researchers also examined fracture healing under metabolic stress. Normally, obesity and impaired glucose metabolism slow down bone regeneration and lead to weaker or even failing repair after injury. However, mice treated with Roxadustat displayed improved fracture healing compared with untreated obese animals that showed compromised bone repair, demonstrating that activation of hypoxia signaling can restore the bone's regenerative potential.
"Our findings show that activation of hypoxia signaling using PHD inhibitors has dual beneficial effects, simultaneously improving metabolism and bone health," says Prof. Maes.
Beyond the experimental findings, the work highlights potential ripple effects across multiple research fields. The hypoxia signaling pathway regulates energy metabolism, vascular biology, and tissue regeneration, making it relevant to studies of diabetes, aging, and regenerative medicine.
In the short term, the findings suggest that therapies activating hypoxia signaling could help reduce bone complications in people with obesity or prediabetes. Over the longer term, such approaches may contribute to treatments that simultaneously manage metabolic disease and strengthen skeletal resilience. If similar effects are confirmed in humans, future therapies could reduce fracture risk, improve recovery after bone injuries, and address metabolic dysfunction in a single integrated strategy.
